Genmab — August 2018

[Mcjean]

JNJ own the rights for Dara, Genmab only get Royalties and milestones so Its JNJ there decide the indikation profile........if i understand u question correct.

[F_L]

"Helge, thank you. I have no intention to post frequently.

[F_L]

@ McJean sorry I meant JNJ. It surprised me they wanted to look at Dara in lung cancer given all the other cheaper therapies that are being developed.

[Plimsoller]

God morgen

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[transalp]

go morgen

[pauly]

mornings

[polle1]

God morgen

[Parasitism]

God Morgen

[gentogen]

Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. June 7, 2018
New England Journal of Med. 2018; 378:2240-2242

[bibob]

Gentogen. Har du et link. ?

[hda]

Just a moment...

(www.nejm.org)

[bibob]

Tak hda. Det lyder da virkelig lovende.

[nohope]

2 patienter -

[E_L]

yes, extremely small disease, we discussed June 7. But it keeps up hope that one day they find it will also work for a bigger disease

[E_L]

The Janssen BCMA CD3 DuoBody was not mentioned in the call was it? Would we expect any data on this this year? Estimated Primary Completion Date is: November 1, 2018

[E_L]

this one https://clinicaltrials.gov/ct2/show/NCT03145181

[Sukkeralf]

Jan said this on my question in Q1 Q&A:

[Sukkeralf]

"Will Janssen report any clinical data from their DuoBody programs in 2018?"
The communication is up to Janssen but we would certainly hope news may come from these programs in 2018.